Neurocrine fleshes out its PhIII case for valbenazine; Avrobio adds to gene therapy pipeline

Neurocrine has already posted the key late-stage data that it took to the FDA in building a case for Ingrezza (valbenazine) as a new therapy for tardive dyskinesia. But now it’s published the full set of data in its favor, including a note that its drug scored for 40% of the patients in the drug arm who registered at least a 50% improvement in AIMS dyskinesia score, compared to 8.7% of those on placebo. Neurocrine is facing a head-to-head fight with a new drug from Teva, and a number of analysts think the smaller biotech has a clear shot at dominating the sector. The PDUFA date for the breakthrough therapy is April 11.

→ Cambridge, MA-based biotech Avrobio is expanding its gene therapy pipeline. Investigators are adding a preclinical program for Gaucher disease, which will follow their Phase I for Fabry disease. CEO Geoff Mackay called it “an excellent strategic fit.”

Aprea Therapeutics, a Karolinska Development company, struck a deal to collaborate with Memorial Sloan Kettering Cancer Center on the effects of reactivating tumor suppressor protein p53 by APR-246.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy

EvaluatePharma World Preview 2017